Skip to main content
SpringerLink
Log in

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily × 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy. Significant hematologic toxicity was observed and was not obviously related to the dose of trimetrexate. No responses were seen in 18 patients. We did not find trimetrexate given as described to be effective in metastatic malignant melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Richter WE, McCormack JJ: Inhibition of mammalian dihydrofolate reductase by selected 2,4-diaminoquinazolines and related compounds. J Med Chem 17:943–947, 1974

    Google Scholar 

  2. Kamen BA, Eibl B, Cashmore A, Bertino J: Uptake and efficacy of trimetrexate, a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol 33:1697–1699, 1984

    Google Scholar 

  3. Fanucchi MP, Walsh TD, Fleisher M, Lokos G, Williams L, Cassidy C, Vidai P, Chou T-C, Niedzwiecki D, Young CW: Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res 47(12):3303–3308, 1987

    Google Scholar 

  4. Stewart JA, McCormack JJ, Tong W, Delap RJ, GrilloLopez AJ: A phase I study of trimetrexate. (Abstr) Proc Am Assoc Cancer Res 26:159, 1985

    Google Scholar 

  5. Donehower RC, Graham ML, Thompson GE, Dole GB, Ettinger DS: Phase I and pharmacokinetic study of trimetrexate (TMTX) in patients with advanced cancer. (Abstr) Proc Am Soc Clin Oncol 4:32, 1985

    Google Scholar 

  6. Eisenhauer EA, Zee BC, Pater JL, Walsh WR: Trimetrexate: Predictors of severe or life-threatening toxicity. J Natl Cancer Inst 80:1318–1322, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Toronto, Toronto, Ontario

    Neill A. Iscoe

  2. Queen's University, Kingston, Ontario

    Elizabeth A. Eisenhauer

  3. Dalhousie University, Halifax, Nova Scotia, Canada

    Audley J. Bodurtha

Authors
  1. Neill A. Iscoe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elizabeth A. Eisenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Audley J. Bodurtha
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iscoe, N.A., Eisenhauer, E.A. & Bodurtha, A.J. Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study. Invest New Drugs 8, 121–123 (1990). https://doi.org/10.1007/BF00216937

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00216937

Key words

Search

Navigation